Resistance-associated mutations in chronic lymphocytic leukemia patients treated with novel agents
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73600809" target="_blank" >RIV/61989592:15110/20:73600809 - isvavai.cz</a>
Alternative codes found
RIV/00098892:_____/20:N0000141
Result on the web
<a href="https://www.frontiersin.org/articles/10.3389/fonc.2020.00894/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Oncology&id=541145" target="_blank" >https://www.frontiersin.org/articles/10.3389/fonc.2020.00894/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Oncology&id=541145</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fonc.2020.00894" target="_blank" >10.3389/fonc.2020.00894</a>
Alternative languages
Result language
angličtina
Original language name
Resistance-associated mutations in chronic lymphocytic leukemia patients treated with novel agents
Original language description
Inhibitors of B-cell receptor signaling, ibrutinib and idelalisib, and BCL-2 antagonist, venetoclax, have become the mainstay of treatment for chronic lymphocytic leukemia (CLL). Despite significant efficacy in most CLL patients, some patients develop resistance to these agents and progress on these drugs. We provide a state-of-the-art overview of the acquired resistance to novel agents. In 80% of patients with ibrutinib failure, acquired mutations in BTK and PLCG2 genes were detected. No distinct unifying resistance-associated mutations or deregulated signaling pathways have been reported in idelalisib failure. Acquired mutations in the BCL2 gene were detected in patients who had failed on venetoclax. In most cases, patients who have progressed on ibrutinib and venetoclax experience resistance-associated mutations, often present at low allelic frequencies. Resistance-associated mutations tend to occur between the second and fourth years of treatment and may already be detected several months before clinical relapse. We also discuss the development of next-generation agents for CLL patients who have acquired resistant mutations to current inhibitors.
Czech name
—
Czech description
—
Classification
Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
<a href="/en/project/NV16-32339A" target="_blank" >NV16-32339A: Impact of functional polymorphisms influencing inflammation and oxidative stress on outcome and selection of treatment in chronic lymphocytic leukemia</a><br>
Continuities
S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in Oncology
ISSN
2234-943X
e-ISSN
—
Volume of the periodical
2020
Issue of the periodical within the volume
10
Country of publishing house
CH - SWITZERLAND
Number of pages
10
Pages from-to
1-10
UT code for WoS article
000549174400001
EID of the result in the Scopus database
2-s2.0-85088278017